Detalles de la búsqueda
1.
A multicenter, randomized, double-blinded, placebo-controlled, phase â ¢ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38366639
2.
Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 190(1): 28-36, 2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37669307
3.
Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.
Dermatol Ther (Heidelb)
; 13(2): 555-567, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566344
4.
[The number of regulatory T cells in spleen and serum-related cytokines increase in mouse model of psoriasis induced by imiquimod].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
; 38(10): 893-897, 2022 Oct.
Artículo
en Zh
| MEDLINE | ID: mdl-36163620
5.
Culture of amelanotic melanocytes derived from human fetal hair follicles.
In Vitro Cell Dev Biol Anim
; 49(9): 689-94, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23813185
6.
Increased frequencies of Th17 and Th22 cells in the peripheral blood of patients with secondary syphilis.
FEMS Immunol Med Microbiol
; 66(3): 299-306, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22775147
Resultados
1 -
6
de 6
1
Próxima >
>>